Drug Profile

Research programme: antisense oligonucleotides - Evotec SE/SynaptixBio

Latest Information Update: 03 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator SynaptixBio
Class Antisense oligonucleotides
Mechanism of Action Gene silencing; TUBB4A protein expression inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Hypomyelinating leukodystrophy-6

Most Recent Events

28 Nov 2024 Preclinical trials in Hypomyelinating leukodystrophy 6 in United Kingdom (Intrathecal) before November 2024
28 Nov 2024 Pharmacokinetics data from a preclinical trials in Hypomyelinating leukodystrophy 6 released by Evotec
30 Apr 2022 Synaptix Bio and Evotec agree to co-develop Antisense oligonucleotides

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com